Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Journal Mobile Options
Table of Contents
Vol. 5, No. 4, 2005
Issue release date: October – December
Section title: Clinical Study
Heart Drug 2005;5:187–192
(DOI:10.1159/000089598)

Comparison of Ticlopidine and Aspirin versus Clopidogrel and Aspirin after Percutaneous Coronary Interventions in High-Risk Patients

A Double-Blind Randomized Study

Di Pasquale P.a · Cannizzaro S.a · Scalzo S.a · Giambanco F.a · Tricoli G.a · Fasullo S.a · Paterna S.b
aDivision of Cardiology Paolo Borsellino, G.F. Ingrassia Hospital, and bDepartment of Internal Medicine, University of Palermo, Palermo, Italy

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

For eJournal Archive and eJournal Backfiles information please contact service@karger.com

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Clinical Study

Received: February 16, 2005
Accepted: April 28, 2005
Published online: December 22, 2005
Issue release date: October – December

Number of Print Pages: 6
Number of Figures: 1
Number of Tables: 4

ISSN: 1422-9528 (Print)
eISSN: 1424-0556 (Online)

For additional information: http://www.karger.com/HED

Abstract

Background: Studies have shown that ticlopidine and clopidogrel in association with aspirin reduce the short- and long-term incidence of major adverse coronary events in patients undergoing stent implantation. Furthermore, clopidogrel seems to show a better side-effect profile than ticlopidine, and recent evidence supports its efficacy in long-term prevention in high-risk patients. Methods: From May 2002 to December 2003, 428 consecutive patients with 1st coronary event underwent a percutaneous coronary intervention (PCI) for non-ST elevation myocardial infarction. All patients received a glycoprotein IIb/IIIa inhibitor and were randomized in double-blind fashion to ticlopidine (500 mg/day) + aspirin or clopidogrel (75 mg/day) + aspirin before PCI. After 48– 72 h, PCI with stent implantation was performed and the treatment was continued for 6 months. Two groups were obtained. The clopidogrel group contained 214 patients (146 M/68 F), mean age 61.3 ± 11.8 years, and the ticlopidine group contained 214 patients (150 M/64 F), mean age 60.7 ± 10.5 years. A protocol that included clinical follow-up at 1, 3 and 6 months was used. Results: Both groups were comparable in baseline characteristics. We observed 14 cases of non-cardiac side effects in the clopidogrel group in the first 30 days after discharge. The ticlopidine group showed 20 non-cardiac side effects (not significant). None of the patients died during the follow-up. Both groups were similar in number of diseased vessels and number of stents. During follow-up (180 days), 48 patients from the clopidogrel group and 44 from the ticlopidine group showed reocclusion in vessels treated with percutaneous transluminal coronary angioplasty (p value not significant). In addition, we observed that reocclusion was mostly evidenced in the first 90 days (44 from the clopidogrel and 40 from the ticlopidine group). In the remaining time (90 days), we observed only 4 cases of reocclusion from the clopidogrel and 4 cases from the ticlopidine group. Conclusion: Our data suggest that ticlopidine or clopidogrel associated with aspirin determine similar effects.

© 2005 S. Karger AG, Basel


Article / Publication Details

First-Page Preview
Abstract of Clinical Study

Received: February 16, 2005
Accepted: April 28, 2005
Published online: December 22, 2005
Issue release date: October – December

Number of Print Pages: 6
Number of Figures: 1
Number of Tables: 4

ISSN: 1422-9528 (Print)
eISSN: 1424-0556 (Online)

For additional information: http://www.karger.com/HED


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.